SCHEMBL6748987

SCHEMBL6748987

CCO[Si](C)(C)c1ccc(N(c2ccc(C)cc2)c2cccc(N(c3ccc(C)cc3)c3ccc(C)cc3)c2)cc1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 3/20 0.32
ADRA1A P35348 3/20 0.32
CYP2C19 P33261 2/20 0.30
LMNA P02545 1/20 0.30
HTR1A P08908 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
CYP2D6 P10635 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
ADRA1D P25100 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
SLC6A4 P31645 1/20 0.30
HRH1 P35367 1/20 0.30
ADRA1B P35368 1/20 0.30
SCN1A P35498 1/20 0.30
OPRK1 P41145 1/20 0.30
HTR2B P41595 1/20 0.30
KCNH2 Q12809 1/20 0.30
SCN2A Q99250 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6745112 0.93 ALDH1A1 (0.33) ADRA2AADRA1ACYP2C19LMNAHTR1A
SCHEMBL6744731 0.91 KMT2A (0.38) MEN1TSHRHTTKMT2ATP53
SCHEMBL6749553 0.91 CYP2C19 (0.39) CYP2C19CYP2D6MEN1TSHRKMT2A
SCHEMBL6745055 0.91 CYP2C19 (0.39) CYP2C19CYP2D6MEN1TSHRKMT2A
SCHEMBL6746704 0.91 CYP2C19 (0.39) CYP2C19CYP2D6MEN1TSHRKMT2A
SCHEMBL6748365 0.91 ALDH1A1 (0.36) CYP2C19CYP2D6MEN1TSHRKMT2A
SCHEMBL6745103 0.91 CYP2C19 (0.39) CYP2C19CYP2D6MEN1TSHRKMT2A
SCHEMBL6748591 0.91 CYP2C19 (0.39) CYP2C19CYP2D6MEN1TSHRKMT2A
SCHEMBL6749512 0.91 ALDH1A1 (0.35) CYP2C19MEN1TSHRKMT2A
SCHEMBL6746764 0.91 ALDH1A1 (0.35) CYP2C19MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696588-B2 OXIDATION POTENTIAL OF .3-1.5 V ON THE BASIS OF A STANDARD HYDROGEN ELECTRODE, ALKOXY AND AROMATIC AMINE DERIVATIVES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-02-24 US disclosed
EP-0861845-B1 Silicon-containing compound and organic electroluminescence device using the same SUMITOMO CHEMICAL CO (JP) 2003-05-28 EP disclosed
US-20020115877-A1 Silicon-containing compound and organic electroluminescence device using the same SUMITOMO CHEMICAL COMPANY, LIMITED 2002-08-22 US disclosed
US-6369258-B1 SILICON COMPOUND WITH OXIDATION POTENTIAL ON HYDROGEN ELECTRODE POTENTIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-04-09 US disclosed
EP-0861845-A2 Silicon-containing compound and organic electroluminescence device using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115877-A1 Silicon-containing compound and organic electroluminescence device using the same EPCAM, PIEZO1, OR10J3 ADRA2A 3494/4885ADRA1A 3023/4885CYP2C19 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.